1541:
1484:
376:
1628:
73:
213:
301:
Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S (February 2018). "Pritumumab, the first therapeutic antibody for glioma patients".
1589:
1525:
499:
463:
380:
278:, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).
1613:
34:
908:
1608:
1582:
1518:
1440:
1109:
1329:
492:
1623:
1618:
966:
893:
798:
1575:
1511:
823:
344:
485:
808:
913:
772:
130:
1457:
551:
1016:
1445:
1412:
1353:
1304:
1219:
843:
1383:
1373:
1343:
1134:
1079:
1006:
996:
873:
1358:
1347:
1309:
1199:
1184:
1114:
1094:
1089:
868:
622:
1209:
1069:
838:
803:
253:
1555:
1491:
1324:
1294:
1289:
1274:
1104:
951:
903:
863:
508:
241:
94:
44:
27:
562:
1046:
597:
557:
400:
377:"Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan"
326:
933:
752:
445:
318:
1559:
1495:
435:
425:
310:
155:
103:
139:
1552:
281:
PTB has been proposed as a potential treatment for COVID-19 and related Viral
Infections.
359:
1548:
1451:
1417:
1084:
440:
413:
1602:
1299:
1154:
707:
542:
1314:
1279:
1264:
1259:
1254:
1249:
1224:
1179:
1174:
1169:
1164:
1149:
1036:
1011:
991:
853:
818:
757:
737:
547:
532:
477:
330:
395:
1422:
1396:
1391:
1363:
1339:
1334:
1269:
1244:
1234:
1204:
1194:
1159:
1144:
1129:
1119:
1099:
1074:
1059:
1031:
981:
976:
971:
956:
946:
923:
918:
888:
833:
777:
767:
742:
732:
727:
722:
697:
672:
662:
657:
652:
642:
627:
612:
607:
592:
587:
577:
572:
567:
537:
268:
1540:
1483:
1368:
1319:
1284:
1214:
1189:
1139:
1124:
1064:
1054:
1026:
1001:
941:
883:
878:
813:
793:
747:
717:
702:
692:
687:
677:
667:
637:
632:
602:
582:
430:
412:
Yu YT, Chien SC, Chen IY, Lai CT, Tsay YG, Chang SC, Chang MF (January 2016).
194:
114:
464:"Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens"
1239:
1229:
1021:
986:
961:
898:
858:
848:
828:
762:
682:
647:
617:
449:
322:
20:
517:
249:
61:
345:"International Nonproprietary Names for Pharmaceutical Substances (INN)"
314:
56:
260:
245:
238:
49:
481:
264:
414:"Surface vimentin is critical for the cell entry of SARS-CoV"
1563:
1499:
220:
399:
for "Safety Study of
Pritumumab in Brain Cancer" at
1405:
1382:
1045:
932:
786:
525:
516:
379:. Nascent Biologics. 1 October 2009. Archived from
193:
154:
149:
129:
113:
93:
88:
72:
67:
55:
43:
33:
26:
102:
1629:Antineoplastic and immunomodulating drug stubs
259:It is in clinical trials for the treatment of
1583:
1519:
493:
252:on the surface of cancer cells. developed by
8:
296:
294:
248:. It works by binding to the ecto-domain of
19:
1590:
1576:
1526:
1512:
522:
500:
486:
478:
439:
429:
138:
290:
18:
7:
1537:
1535:
1480:
1478:
1562:. You can help Knowledge (XXG) by
1498:. You can help Knowledge (XXG) by
14:
1614:Monoclonal antibodies for tumors
1539:
1482:
172:
166:
1609:Drugs not assigned an ATC code
184:
178:
160:
1:
418:Journal of Biomedical Science
1645:
1534:
1477:
150:Chemical and physical data
1624:Monoclonal antibody stubs
1619:Experimental cancer drugs
1435:
1017:Mirvetuximab soravtansine
431:10.1186/s12929-016-0234-7
358:(1). 2004. Archived from
210:
1413:Depatuxizumab mafodotin
1354:Tucotuzumab celmoleukin
1305:Rovalpituzumab tesirine
1220:Lorvotuzumab mertansine
1110:Clivatuzumab tetraxetan
1494:–related article is a
1374:Vorsetuzumab mafodotin
1330:Tacatuzumab tetraxetan
1135:Denintuzumab mafodotin
1080:Bivatuzumab mertansine
1007:Loncastuximab tesirine
997:Indatuximab ravtansine
874:Naptumomab estafenatox
468:Financialnewsmedia.com
393:Clinical trial number
1359:Vandortuzumab vedotin
1310:Sacituzumab govitecan
1200:Inotuzumab ozogamicin
1185:Gemtuzumab ozogamicin
1115:Cofetuzumab pelidotin
1095:Cantuzumab ravtansine
1090:Cantuzumab mertansine
909:Nofetumomab merpentan
869:Moxetumomab pasudotox
623:Glembatumumab vedotin
509:Monoclonal antibodies
271:designation in 2015.
1406:Chimeric + humanized
1210:Lifastuzumab vedotin
1070:Belantamab mafodotin
839:Ibritumomab tiuxetan
804:Anatumomab mafenatox
365:on 11 February 2012.
352:WHO Drug Information
1492:monoclonal antibody
1325:Sofituzumab vedotin
1295:Polatuzumab vedotin
1290:Pinatuzumab vedotin
1275:Oportuzumab monatox
1105:Citatuzumab bogatox
967:Derlotuximab biotin
952:Brentuximab vedotin
904:Taplitumomab paptox
894:Satumomab pendetide
864:Nacolomab tafenatox
799:Altumomab pentetate
242:monoclonal antibody
28:Monoclonal antibody
23:
16:Monoclonal antibody
1462:Never to phase III
824:Capromab pendetide
598:Enfortumab vedotin
401:ClinicalTrials.gov
315:10.3233/HAB-170326
1571:
1570:
1507:
1506:
1472:
1471:
1431:
1430:
753:Tisotumab vedotin
244:targeted against
228:
227:
1636:
1592:
1585:
1578:
1553:immunomodulatory
1543:
1536:
1528:
1521:
1514:
1486:
1479:
1384:Rat/mouse hybrid
523:
502:
495:
488:
479:
472:
471:
460:
454:
453:
443:
433:
409:
403:
391:
385:
384:
373:
367:
366:
364:
349:
341:
335:
334:
303:Human Antibodies
298:
224:
223:
216:
205:
203:
186:
180:
174:
168:
162:
142:
106:
24:
22:
1644:
1643:
1639:
1638:
1637:
1635:
1634:
1633:
1599:
1598:
1597:
1596:
1533:
1532:
1475:
1473:
1468:
1467:
1452:Clinical trials
1427:
1401:
1378:
1041:
928:
782:
512:
506:
476:
475:
470:. 17 June 2020.
462:
461:
457:
411:
410:
406:
392:
388:
375:
374:
370:
362:
347:
343:
342:
338:
300:
299:
292:
287:
254:Nascent Biotech
219:
217:
214:(what is this?)
211:
201:
199:
189:
183:
177:
171:
165:
145:
125:
109:
84:
17:
12:
11:
5:
1642:
1640:
1632:
1631:
1626:
1621:
1616:
1611:
1601:
1600:
1595:
1594:
1587:
1580:
1572:
1569:
1568:
1549:antineoplastic
1544:
1531:
1530:
1523:
1516:
1508:
1505:
1504:
1487:
1470:
1469:
1466:
1465:
1464:
1463:
1460:
1449:
1443:
1437:
1436:
1433:
1432:
1429:
1428:
1426:
1425:
1420:
1418:Duvortuxizumab
1415:
1409:
1407:
1403:
1402:
1400:
1399:
1394:
1388:
1386:
1380:
1379:
1377:
1376:
1371:
1366:
1361:
1356:
1351:
1337:
1332:
1327:
1322:
1317:
1312:
1307:
1302:
1297:
1292:
1287:
1282:
1277:
1272:
1267:
1262:
1257:
1252:
1247:
1242:
1237:
1232:
1227:
1222:
1217:
1212:
1207:
1202:
1197:
1192:
1187:
1182:
1177:
1172:
1167:
1162:
1157:
1152:
1147:
1142:
1137:
1132:
1127:
1122:
1117:
1112:
1107:
1102:
1097:
1092:
1087:
1085:Brontictuzumab
1082:
1077:
1072:
1067:
1062:
1057:
1051:
1049:
1043:
1042:
1040:
1039:
1034:
1029:
1024:
1019:
1014:
1009:
1004:
999:
994:
989:
984:
979:
974:
969:
964:
959:
954:
949:
944:
938:
936:
930:
929:
927:
926:
921:
916:
911:
906:
901:
896:
891:
886:
881:
876:
871:
866:
861:
856:
851:
846:
841:
836:
831:
826:
821:
816:
811:
806:
801:
796:
790:
788:
784:
783:
781:
780:
775:
770:
765:
760:
755:
750:
745:
740:
735:
730:
725:
720:
715:
710:
705:
700:
695:
690:
685:
680:
675:
670:
665:
660:
655:
650:
645:
640:
635:
630:
625:
620:
615:
610:
605:
600:
595:
590:
585:
580:
575:
570:
565:
560:
555:
552:+hyaluronidase
545:
540:
535:
529:
527:
520:
514:
513:
507:
505:
504:
497:
490:
482:
474:
473:
455:
404:
386:
383:on 2011-07-14.
368:
336:
289:
288:
286:
283:
274:The target of
226:
225:
208:
207:
197:
191:
190:
187:
181:
175:
169:
163:
158:
152:
151:
147:
146:
144:
143:
135:
133:
127:
126:
124:
123:
119:
117:
111:
110:
108:
107:
99:
97:
91:
90:
86:
85:
83:
82:
78:
76:
70:
69:
65:
64:
59:
53:
52:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1641:
1630:
1627:
1625:
1622:
1620:
1617:
1615:
1612:
1610:
1607:
1606:
1604:
1593:
1588:
1586:
1581:
1579:
1574:
1573:
1567:
1565:
1561:
1558:article is a
1557:
1554:
1550:
1545:
1542:
1538:
1529:
1524:
1522:
1517:
1515:
1510:
1509:
1503:
1501:
1497:
1493:
1488:
1485:
1481:
1476:
1461:
1459:
1456:
1455:
1453:
1450:
1447:
1444:
1442:
1439:
1438:
1434:
1424:
1421:
1419:
1416:
1414:
1411:
1410:
1408:
1404:
1398:
1395:
1393:
1390:
1389:
1387:
1385:
1381:
1375:
1372:
1370:
1367:
1365:
1362:
1360:
1357:
1355:
1352:
1349:
1345:
1341:
1338:
1336:
1333:
1331:
1328:
1326:
1323:
1321:
1318:
1316:
1313:
1311:
1308:
1306:
1303:
1301:
1300:Rosmantuzumab
1298:
1296:
1293:
1291:
1288:
1286:
1283:
1281:
1278:
1276:
1273:
1271:
1268:
1266:
1263:
1261:
1258:
1256:
1253:
1251:
1248:
1246:
1243:
1241:
1238:
1236:
1233:
1231:
1228:
1226:
1223:
1221:
1218:
1216:
1213:
1211:
1208:
1206:
1203:
1201:
1198:
1196:
1193:
1191:
1188:
1186:
1183:
1181:
1178:
1176:
1173:
1171:
1168:
1166:
1163:
1161:
1158:
1156:
1155:Enoblituzumab
1153:
1151:
1148:
1146:
1143:
1141:
1138:
1136:
1133:
1131:
1128:
1126:
1123:
1121:
1118:
1116:
1113:
1111:
1108:
1106:
1103:
1101:
1098:
1096:
1093:
1091:
1088:
1086:
1083:
1081:
1078:
1076:
1073:
1071:
1068:
1066:
1063:
1061:
1058:
1056:
1053:
1052:
1050:
1048:
1044:
1038:
1035:
1033:
1030:
1028:
1025:
1023:
1020:
1018:
1015:
1013:
1010:
1008:
1005:
1003:
1000:
998:
995:
993:
990:
988:
985:
983:
980:
978:
975:
973:
970:
968:
965:
963:
960:
958:
955:
953:
950:
948:
945:
943:
940:
939:
937:
935:
931:
925:
922:
920:
917:
915:
912:
910:
907:
905:
902:
900:
897:
895:
892:
890:
887:
885:
882:
880:
877:
875:
872:
870:
867:
865:
862:
860:
857:
855:
852:
850:
847:
845:
842:
840:
837:
835:
832:
830:
827:
825:
822:
820:
817:
815:
812:
810:
807:
805:
802:
800:
797:
795:
792:
791:
789:
785:
779:
776:
774:
771:
769:
766:
764:
761:
759:
756:
754:
751:
749:
746:
744:
741:
739:
736:
734:
731:
729:
726:
724:
721:
719:
716:
714:
711:
709:
708:Pembrolizumab
706:
704:
701:
699:
696:
694:
691:
689:
686:
684:
681:
679:
676:
674:
671:
669:
666:
664:
661:
659:
656:
654:
651:
649:
646:
644:
641:
639:
636:
634:
631:
629:
626:
624:
621:
619:
616:
614:
611:
609:
606:
604:
601:
599:
596:
594:
591:
589:
586:
584:
581:
579:
576:
574:
571:
569:
566:
564:
561:
559:
556:
553:
549:
546:
544:
543:Ascrinvacumab
541:
539:
536:
534:
531:
530:
528:
524:
521:
519:
515:
510:
503:
498:
496:
491:
489:
484:
483:
480:
469:
465:
459:
456:
451:
447:
442:
437:
432:
427:
423:
419:
415:
408:
405:
402:
398:
397:
390:
387:
382:
378:
372:
369:
361:
357:
353:
346:
340:
337:
332:
328:
324:
320:
316:
312:
309:(2): 95–101.
308:
304:
297:
295:
291:
284:
282:
279:
277:
272:
270:
266:
262:
257:
255:
251:
247:
243:
240:
236:
232:
222:
215:
209:
198:
196:
192:
159:
157:
153:
148:
141:
137:
136:
134:
132:
128:
121:
120:
118:
116:
112:
105:
101:
100:
98:
96:
92:
87:
80:
79:
77:
75:
71:
68:Clinical data
66:
63:
60:
58:
54:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1564:expanding it
1546:
1500:expanding it
1489:
1474:
1315:Sibrotuzumab
1280:Parsatuzumab
1265:Otlertuzumab
1260:Odronextamab
1255:Ocaratuzumab
1250:Obinutuzumab
1225:Lumretuzumab
1180:Flotetuzumab
1175:Ficlatuzumab
1170:Farletuzumab
1165:Etaracizumab
1150:Emibetuzumab
1037:Zolbetuximab
1012:Margetuximab
992:Girentuximab
854:Minretumomab
819:Blinatumomab
758:Teprotumumab
738:Seribantumab
712:
563:Botensilimab
548:Atezolizumab
533:Adecatumumab
467:
458:
421:
417:
407:
394:
389:
381:the original
371:
360:the original
355:
351:
339:
306:
302:
280:
275:
273:
258:
234:
230:
229:
218:
212:
1448:from market
1423:Ontuxizumab
1397:Ertumaxomab
1392:Catumaxomab
1364:Vanucizumab
1344:+deruxtecan
1340:Trastuzumab
1335:Tigatuzumab
1270:Onartuzumab
1245:Nimotuzumab
1235:Milatuzumab
1205:Labetuzumab
1195:Imgatuzumab
1160:Epcoritamab
1145:Emactuzumab
1130:Dalotuzumab
1120:Dacetuzumab
1100:Cirmtuzumab
1075:Bevacizumab
1060:Alemtuzumab
1032:Ublituximab
982:Ensituximab
977:Ecromeximab
972:Dinutuximab
957:Carotuximab
947:Bavituximab
924:Tositumomab
919:Tenatumomab
889:Racotumomab
834:Edrecolomab
809:Arcitumomab
778:Zalutumumab
768:Vantictumab
743:Sugemalimab
733:Robatumumab
728:Rilotumumab
723:Ramucirumab
698:Panitumumab
673:Necitumumab
663:Mapatumumab
658:Lucatumumab
653:Lexatumumab
643:Istiratumab
628:Intetumumab
613:Flanvotumab
608:Figitumumab
593:Dusigitumab
588:Duligotumab
578:Daratumumab
573:Conatumumab
568:Cixutumumab
558:Balstilimab
538:Amivantamab
396:NCT04396717
269:orphan drug
206: g·mol
104:499212-74-7
89:Identifiers
1603:Categories
1369:Veltuzumab
1348:+emtansine
1320:Simtuzumab
1285:Pertuzumab
1215:Lintuzumab
1190:Glofitamab
1140:Elotuzumab
1125:Demcizumab
1065:Axatilimab
1055:Abituzumab
1027:Siltuximab
1002:Isatuximab
942:Amatuximab
914:Pintumomab
884:Pemtumomab
879:Oregovomab
814:Bectumomab
794:Abagovomab
748:Tarextumab
718:Radretumab
713:Pritumumab
703:Patritumab
693:Olaratumab
688:Ofatumumab
678:Nesvacumab
668:Narnatumab
638:Iratumumab
633:Ipilimumab
603:Enoticumab
583:Drozitumab
511:for tumors
285:References
276:Pritumumab
231:Pritumumab
195:Molar mass
140:Z6Q90D1G53
115:ChemSpider
95:CAS Number
21:Pritumumab
1458:Phase III
1446:Withdrawn
1240:Naxitamab
1230:Matuzumab
1047:Humanized
1022:Rituximab
987:Futuximab
962:Cetuximab
899:Solitomab
859:Mitumomab
849:Lilotomab
829:Detumomab
773:Votumumab
763:Tovetumab
683:Nivolumab
648:Icrucumab
618:Ganitumab
934:Chimeric
844:Igovomab
450:26801988
323:29036806
267:granted
250:vimentin
221:(verify)
74:ATC code
62:vimentin
441:4724099
331:3266191
237:) is a
156:Formula
1441:WHO-EM
448:
438:
424:: 14.
329:
321:
263:. The
261:glioma
246:glioma
57:Target
45:Source
1547:This
1490:This
787:Mouse
526:Human
518:Tumor
363:(PDF)
348:(PDF)
327:S2CID
239:human
50:Human
1560:stub
1556:drug
1496:stub
446:PMID
319:PMID
182:2016
176:1708
170:9968
164:6440
131:UNII
122:none
81:none
35:Type
1551:or
436:PMC
426:doi
311:doi
265:FDA
235:PTB
204:.04
202:923
200:144
1605::
1454::
1346:/
466:.
444:.
434:.
422:23
420:.
416:.
356:18
354:.
350:.
325:.
317:.
307:26
305:.
293:^
256:.
188:42
1591:e
1584:t
1577:v
1566:.
1527:e
1520:t
1513:v
1502:.
1350:)
1342:(
554:)
550:(
501:e
494:t
487:v
452:.
428::
333:.
313::
233:(
185:S
179:O
173:N
167:H
161:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.